Compare TG Therapeutics Inc (TGTX) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard S&P 500 ETF — how do they compare? TG Therapeutics Inc trades at $54.98 (market cap $8.16B), while Vanguard S&P 500 ETF trades at $715.55 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 220.6× TG Therapeutics Inc's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard S&P 500 ETF for 55 Days on average.
| TGTX | VOO | |
|---|---|---|
Market Cap | $8.16B | $1.80T |
Volume | 1,735,121 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $716.17 |
52-Week Low | $26.94 | $580.93 |
Typical Hold Time | 16 Days | 55 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VOO trades at $715.68, up 0.18% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building despite short interest increasing 46.9% in September. Dividend yield remains modest with the next payment scheduled for September 30, 2026.
Outlook remains positive given S&P 500 exposure and historical resilience, though risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated short interest. The ETF's low-cost structure and diversification provide stability amid market volatility, making it suitable for core portfolio holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
